RVPH — Reviva Pharmaceuticals Holdings Cashflow Statement
0.000.00%
- $40.52m
- $27.50m
Annual cashflow statement for Reviva Pharmaceuticals Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 February 29th | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 0.618 | -8.52 | -24.3 | -39.3 | -29.9 |
Depreciation | |||||
Non-Cash Items | -1.34 | -1.44 | 0.371 | 3.65 | 0.913 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.298 | -0.702 | 5.01 | 7.28 | -4.54 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -0.427 | -10.7 | -19 | -28.3 | -33.5 |
Other Investing Cash Flow Items | 5.7 | — | — | — | — |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 5.7 | — | — | — | — |
Financing Cash Flow Items | 0 | 0 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -5.52 | 31.6 | 7.79 | 33.2 | 23.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.244 | 20.9 | -11.2 | 4.85 | -9.89 |